Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Submits Seroquel XR In Two Additional Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is seeking approval of separate sNDAs for treatment of bipolar mania and bipolar depression.

You may also be interested in...



Lundbeck’s Serdolect and AstraZeneca’s Seroquel XR To Face Advisory Panel Review

FDA’s Psychopharmacologic Drug Advisory Committee will evaluate the applications for the two antipsychotics in a two day meeting in April.

Lundbeck’s Serdolect and AstraZeneca’s Seroquel XR To Face Advisory Panel Review

FDA’s Psychopharmacologic Drug Advisory Committee will evaluate the applications for the two antipsychotics in a two day meeting in April.

Antipsychotic Not Certain Savior For Forest

Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.

Related Content

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel